Company intelligence / Profile preview
Arisaph Pharmaceuticals
Boston, Massachusetts, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Arisaph Pharmaceuticals develops novel small molecule drugs and peptides targeting validated pathways in cardiometabolic diseases and cancer. Its lead candidate ARI‑3037MO, a niacin analog designed to treat dyslipidemias without the flushing side effect of traditional niacin therapy, has advanced through Phase I with favorable safety data and into Phase II trials for cardiovascular indications. The company also has preclinical programs in oncology using tumor activated prodrugs and immune modulators. Arisaph leverages proprietary medicinal chemistry platforms licensed from Tufts University.[3][6]
- Therapeutic areas
- GastroenterologyOncologyEndocrinologyCardiovascular
- Modalities
- Small molecules[3][6]Peptides (apo A-I mimetic peptide)[8]Prodrugs[5]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Royalty Pharma—cross-license relating to DPP-IV patent estate acquired from Astellas Pharma Inc.[3]
Beyond the preview
Go deeper on Arisaph Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arisaph Pharmaceuticals.